Close mobile menu×
Close mobile menu

Julia J. Wattacheril, MD, MPH

Board Certifications: 
Gastroenterology, Transplant Hepatology, Internal Medicine
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-0914

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

Board Certifications

  • Gastroenterology
  • Transplant Hepatology
  • Internal Medicine

Clinical Expertise

  • Nonalcoholic fatty liver disease
  • Liver Transplantation
  • Liver Cancer
  • Chronic Liver Disease
  • Hepatitis

Education & Training

  • Baylor College of Medicine
  • Residency: Baylor Hospital
  • Fellowship: Vanderbilt University Medical Center
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

About Julia Wattacheril

Dr. Wattacheril's clinical specialties include all aspects of transplant hepatology, general hepatology and gastroenterology with emphasis on metabolic liver disease and obesity. She specializes in nonalcoholic fatty liver disease as well as all forms of hepatitis, chronic liver disease, and liver cancer in addition to liver transplantation. Her research interests include hepatic steatosis, insulin resistance, gut hormones and metabolic liver disease in adults. Her current research concentrates on the relationship between proteins and lipids that differentiate steatosis from steatohepatitis using an integrated omics approach.

Academic Titles

  • Assistant Professor of Medicine at CUMC

Administrative Positions

  • Director of the Nonalcoholic Fatty Liver Disease Program

Hospital Affiliations

  • NewYork-Presbyterian/Weill Cornell
  • NewYork-Presbyterian/Columbia

Gender

  • Female

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Access (Exchange)
  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Medicare

  • Traditional Medicare (NY)

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

POMCO

  • POMCO

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
622 West 168th Street
New York, New York 10032
Phone: (212) 305-0914
Primary

Research

Hepatic steatosis, insulin resistance and metabolic liver disease in adults. Her current grant concentrates on the proteins and lipids that signal the transition from steatosis to steatohepatitis.

Research Interests

  • Non-alcoholic fatty liver disease (including non-alcoholic steatohepatitis)
  • Transplant hepatology
  • Hepatocellular carcinoma
  • Metabolic liver diseases
  • OMICs
  • Lipid metabolism
  • Insulin resistance

Grants

PHASE 2 DOUBLE-BLIND,RANDOMIZED,PLACEBO-CONTROLLED,DOSE-FINDING STUDY TO EVALUATE SAFETY,TOLERABILITY & EFFICACY OF VOLIXIBAT POTASSIUM,AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR(ASBTI) IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS(NASH) (P&S Industry Clinical Trial)

May 11 2017 - May 11 2022

CLINICAL RESEARCH ON NONALCOHOLIC FATTY LIVER DISEASE (Federal Gov)

Jul 1 2014 - Jun 30 2019

A PHASE 2B, DOSE RANGING, RANDOMIZED, DOUBLE- BLIND, PLACEBO- CONTROLLED TRIAL EVALUATING THE SAFETY AND EFFICACY OF GS 6624, A MONOCLONAL ANTIBODY AGAINST LYSYL OXIDASE LIKE 2 (LOXL2), IN SUBJECTS WITH COMPENSATED CIRRHOSIS SECONDARY (P&S Industry Clinical Trial)

Jan 14 2014 - Jan 14 2019

A PHASE 2B, DOSE RANGING, RANDOMIZED, DOUBLE BLIND, PLACEBO- CONTROLLED TRIAL EVALUATING THE SAFETY AND EFFICACY OF GS 6624, A MONOCLONAL ANTIBODY AGAINST LYSYL OXIDASE- LIKE 2 (LOXL2), IN SUBJECTS WITH ADVANCED LIVER FIBROSIS BUT NOT CIRRHOSIS SECONDARY (P&S Industry Clinical Trial)

Jan 14 2014 - Jan 14 2019

Selected Publications

  1. Corey KE, Gawrieh S, deLemos AS, Zheng H, Scanga AE, Haglund JW, Sanchez J, Danford CJ, Comerford M, Bossi K, Munir S, Chalasani N, Wattacheril J. Risk factors for hepato­cellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study. World J Hepatol 2017; 9(7): 385-390
  2. Wattacheril, J, Rose, K. L., Hill, S., Lanciault, C., Murray, C. R., Washington, K., Williams, B., English, W., Spann, M., Clements, R., Abumrad, N., and Flynn, C. R. (2017) NAFLD Phosphoproteomics: A Functional Piece of the Precision Puzzle. Hepatol Res, doi: 10.1111/hepr.12885.
  3. Wattacheril J, Sanyal AJ. Lean NAFLD: An Underrecognized Outlier. Curt Hepatol Rep. 2016 Jun;15(2):134-139, Epub 2016 Apr 14. PMID: 27668144
  4. Guo Y, Xiong Y, Sheng Q, Zhao S, Wattacheril J, Flynn CR. A micro-RNA expression signature for human NAFLD progression. J Gastroenterol. 2016 Feb 13.
  5. Wattacheril, Julia and Joseph Awad. “Acute Management of Portal Hypertensive Bleeding” Jarnagin & Blumgart: Blumgart's Surgery of the Liver, Biliary Tract, and Pancreas 5/e, 2012, 2016
  6. Garcia A, Kasim N, Gonzalez, R, Antoun J, Eckert E, Marks P, Wattacheril J, Abumrad N, Tamboli R, Walle T, Dunn J, Flynn CR. Lipoprotein Profiles in Class III Obese Caucasian and African American Women with Nonalcoholic Fatty Liver Disease. PLoS One. 2015 Nov 23;10(11):e0142676. dos: 10.1371/journal.pone.0142676
  7. Sharifnia T, Antoun J, Suarez G, Wattacheril J, Wilson K, Peek RM, Abumrad N, and Flynn CF. Hepatic TLR4 Signaling in Obese NAFLD. Am J Physiol Gastrointest Liver Physiol. 2015 Aug 15;309(4):G270-8. doi: 10.1152/ajpgi.00304.2014
  8. Wattacheril J, Seeley EH, Angel P, Chen H, Bowen BP, et al. (2013) Differential Intrahepatic Phospholipid Zonation in Simple Steatosis and Nonalcoholic Steatohepatitis. PLoS ONE 8(2): e57165. doi:10.1371/journal.pone.0057165
  9. Wattacheril, J. and Chalasani, N. (2012), Nonalcoholic fatty liver disease (NAFLD): Is it really a serious condition?. Hepatology, 56: 1580–1584. doi: 10.1002/hep.26031
  10. Wattacheril, J. and Chalasani, N. (2012), Management of nonalcoholic fatty liver disease: Role of bariatric surgery. Clinical Liver Disease, 1: 118–120. doi: 10.1002/cld.80
  11. Wattacheril, J and Brown, RS. “Living Donor Transplantation for Adult Acute Liver Failure”, Controversies in Hepatology: The Experts Analyze Both Sides. Editor: Donald Jensen. Thorofare, New Jersey, Slack Inc, 2011. ISBN: 13 978-1-55642-950-7
  12. Hajri, Tahar, Huan Tao, Julia Wattacheril, Pamela Marks-Shulman and Naji Abumrad. Regulation of adiponectin production by insulin: Interactions with tumor necrosis factor-α and interleukin 6. Am J Physiol Endocrinol Metab 2011 Feb 300(2): E350–E360. PMID: 21062957.
  13. Abumrad NN, Breitman I, Wattacheril J, Hubbard WJ, Chaudry IH. “Metabolic and Inflammatory Responses in Trauma and Infection”, Mastery of Surgery sixth edition, Joseph E. Fischer (editor), 2011, pp. 1-25
  14. Saliba J, Wattacheril J, Abumrad NN (2009) Endocrine and metabolic response to gastric bypass. Curr Opin Clin Nutr Metab Care, 12:515-21. Review. PMID: 19535977
  15. Wattacheril J, Kramer JR, Richardson P, Havemann BD, Green LK, Le A, El-Serag HB (2008). Lagtimes in diagnosis and treatment of colorectal cancer: determinants and association with cancer stage and survival. Aliment Pharmacol Ther, 28:1166-74. PMID: 18691351.